drugset
drugset / Trial / NCT03509545

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

NCT03509545 ↗

Phase 1 Terminated 20 enrolled Sarfez Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Timeline

Start
2021-06-30
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Furosemide Other / unclassified 40 mg —
Subject Torsemide Other / unclassified 40 mg —

Indications

No indication recorded.